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Haemostatic and inflammatory biomarkers in advanced chronic
heart failure: role of oral anticoagulants and successful heart
transplantation
Neuroendocrine mechanisms (i.e. activation of the renin-
angiotensin and sympathetic nervous systems) are major
contributors to the haemodynamic abnormalities that lead to
symptoms in chronic congestive heart failure (CHF) and
structural changes in left ventricle remodelling (Francis et al,
1984; Pfeffer & Pfeffer, 1988; Cohn, 2001), but there is a
growing body of evidence indicating that cytokine-mediated
immunological responses also play a role in the pathogenesis of
heart failure (Finkel et al, 1992; Bozkurt et al, 1998). Since the
first report of high serum tumour necrosis factor-a (TNF a)
levels in CHF patients (Levine et al, 1990), a number of studies
have shown that other proinflammatory cytokines and chem-
okines are involved in cardiac depression and the progression
of heart failure (Aukrust et al, 1998; Kapadia et al, 1998;
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Summary
Advanced chronic heart failure (CHF) is associated with abnormal
haemostasis and inflammation, but it is not known how these
abnormalities are related, whether they are modified by oral anticoagulants
(OAT), or if they persist after successful heart transplantation. We studied 25
patients with CHF (New York Heart Association class IV, 10 of whom
underwent heart transplantation) and 25 age- and sex-matched healthy
controls by measuring their plasma levels of prothrombin fragment 1 + 2
(F1 + 2), thrombin–antithrombin (TAT) complexes, tissue plasminogen
activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), D-dimer, factor
VII (FVII), fibrinogen, von Willebrand factor (VWF), tumour necrosis
factor (TNF), soluble TNF receptor II (sTNFRII), interleukin 6 (IL-6),
soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell
adhesion molecule-1 (sVCAM-1), endothelial-selectin (E-selectin) and
thrombomodulin. CHF patients had higher plasma levels of TAT, D-dimer,
t-PA, fibrinogen, VWF, TNF, IL-6, sTNFRII, sVCAM-1 (P ¼ 0Æ0001),
sICAM-1 (P ¼ 0Æ003) and thrombomodulin (P ¼ 0Æ007) than controls.
There were significant correlations (r ¼ 0Æ414–0Æ595) between coagulation,
fibrinolysis, endothelial dysfunction and inflammation parameters, which
were lower in those patients treated with OATs. Heart transplantation led to
reductions in fibrinogen (P ¼ 0Æ001), VWF (P ¼ 0Æ05), D-dimer (P ¼ 0Æ05)
and IL-6 levels (P ¼ 0Æ05), but all the parameters remained significantly
higher (P ¼ 0Æ01–0Æ0001) than in the controls. Advanced CHF is associated
with coagulation activation, endothelial dysfunction and increased
proinflammatory cytokine levels. Most of these abnormalities parallel each
other, tend to normalize in patients treated with OATs and, although
reduced, persist in patients undergoing successful heart transplantation,
despite the absence of clinical signs of CHF.
Keywords: coagulation, inflammation, heart failure, oral anticoagulants,
heart transplantation.
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Sharma et al, 2000), and new lines of evidence suggest that
cytokines can be considered treatment targets (Baumgarten
et al, 2000).
Chronic heart failure is also associated with endothelial and
blood coagulation abnormalities that may lead to progressive
heart disease, and the increased risk of stroke and venous
thromboembolism (Lip & Gibbs, 1999; Davis et al, 2000) in
patients with severe CHF (Diet & Erdmann, 2000). It has been
shown that haemostatic abnormalities are correlated with
neuroendocrine activation in CHF (Sbarouni et al, 1994) but
their relationship with cytokines and inflammation is unclear,
although the modulatory role of cytokines on haemostasis is
well known (Kerr et al, 2001).
Proinflammatory cytokines are also related to endothelial
dysfunction in heart transplant recipients (Aukrust et al, 2000)
and contribute to the development of transplant coronary
artery disease (Gullestad et al, 1999). Heart transplant recip-
ients also show prothrombotic changes that tend to be more
evident in patients with accelerated coronary sclerosis (Hunt
et al, 1993).
The aim of this study was to investigate the haemostatic,
endothelial and inflammatory abnormalities in patients with
advanced heart failure in order to determine their possible
relationships, and to see whether they are modified by oral
anticoagulants (OATs) or persist after successful heart trans-
plantation.
Methods
Patients
The study was performed according to the ethical guidelines of
the Declaration of Helsinki, and all of the subjects gave their
informed consent before participating.
We studied 25 male patients aged 22–65 years (mean ± SD,
54 ± 10) with advanced CHF [New York Heart Association
(NYHA) class IV] who were consecutively admitted to the
University Department of Cardiology during the course of
1 year. The patient’s clinical, haemodynamic and biochemical
characteristics are shown in Table I. All of the patients were
treated with diuretics, angiotensin-converting enzyme (ACE)-
inhibitors, beta-blockers and anti-aldosterone; 11 also received
OAT treatment designed to maintain a prothrombin time
international normalized ratio (INR) of between 2 and 3.
Although the patients receiving and not receiving OAT
treatment were not identical, there was no significant clinical
difference between the groups in terms of the aetiology of
CHF, left ventricular ejection fraction, blood pressure or
routine laboratory parameters.
After 4 ± 3 months, 10 of the 25 patients underwent
transplantation, nine of whom (age 22–62 years; mean
51 ± 14) were re-evaluated after a period of 24 ± 7 months.
Prior to heart transplantation, these nine patients had clinical
conditions and laboratory tests similar to those observed in the
untransplanted patients and 44% of the patients in both
groups were treated with OATs. The ischaemic period of the
cardiac grafts ranged from 120 to 320 min. At the time of the
re-evaluation, all of the transplant patients were clinically and
haemodynamically stable (NYHA class I) and had shown no
signs of rejection or infection in the previous 6 months; none
of them was receiving OATs. Five were treated with ciclosp-
orin, prednisolone and azathioprine (one of whom discontin-
ued prednisolone because of major side effects 6 months
before the date of blood collection); the remaining four
received only ciclosporin and prednisolone.
Controls
The control group consisted of 25 age-matched male healthy
subjects.
Blood sampling
After an overnight fast, 23 ml of blood were collected in the
morning into polypropylene tubes containing different anti-
coagulant mixtures: (i) sodium citrate 3Æ8% (1 ml of antico-
agulant/9 ml of blood) for the measurement of tissue
plasminogen activator (t-PA), D-dimer fragment, prothrom-
bin fragment 1 + 2 (F1 + 2), thrombin–antithrombin (TAT)
complexes, fibrinogen, von Willebrand factor (VWF) antigen,
factor VII (FVII), activated factor XII (FXIIa) and thrombo-
modulin; (ii) ethylenediaminetetraacetic acid sodium salt
(EDTA) 200 mmol/l (0Æ250 ml of anticoagulant/5 ml of
blood) to determine the levels of interleukin-6 (IL-6), TNFa,
Table I. Clinical, haemodynamic and laboratory parameters in 25
patients with advanced heart failure.
Patients (n) 25
Age (years, mean ± SD) 54 ± 11
Males (n) 25
NYHA Class IV advanced (n) 25
Aetiology
Ischaemic (n) 11
Idiopathic (n) 13
Valvular (n) 1
Left ventricular ejection fraction (% mean ± SD) 21 ± 5
Systolic blood pressure (mmHg, mean ± SD) 101 ± 8
Diastolic blood pressure (mmHg, mean ± SD) 65 ± 7
Treatment
Furosemide (mg/d) 50–500
Potassium canrenoate (mg/d) 25–100
Enalapril (mg/d) 10–20
Laboratory
Serum creatinine (lmol/l, mean ± SD) 148 ± 68
Serum cholinesterase(U/L, mean ± SD) 7721 ± 2182
Serum bilirubin (lmol/l, mean ± SD) 21 ± 9Æ0
Serum sodium (mmol/l, mean ± SD) 131 ± 7
Serum potassium (mmol/l, mean ± SD) 4Æ23 ± 0Æ47
Haemoglobin (g/dl, mean ± SD) 12Æ9 ± 2Æ0
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soluble TNF receptor II (sTNFRII), soluble intercellular
adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion
molecule-1 (sVCAM-1) and soluble endothelial selectin
(sE-selectin); (iii) prechilled 0Æ5 mol/l citrated buffer pH 4Æ3
(Stabilyte, Biopool, Umea, Sweden) (0Æ5 ml of anticoagulant/
4Æ5 ml of blood) for the plasminogen activator inhibitor-1
(PAI1) assay and (iv) a cocktail containing protease inhibitors
(100 mmol/l trisodium citrate, 67 mmol/l citric acid and 2%
dextrose, pH 4Æ5, 100 mmol/l benzamidine, 400 lg/ml hexad-
imethrine bromide, 2 mg/ml soybean trypsin inhibitor,
263 lmol/l leupeptin and 20 mmol/l aminoethylbenzenesul-
phonylfluoride) (0Æ5 ml of anticoagulant/4Æ5 ml of blood) for
the evaluation of cleaved high-molecular-weight kininogen
(HK). Plasma aliquots of 0Æ4 ml were frozen and stored at
)80C until testing when they were thawed for 10 min in a
water bath at 37C.
Biomarkers
Fibrinogen was measured by means of a commercial coagul-
ometric method (Diagnostica Stago, Asnie`res, France).
TAT complexes were measured using a sandwich enzyme-
linked immunosorbent assay (ELISA; Enzygnost TAT micro,
Behring Diagnostics GmbH, Marburg, Germany) with intra-
and inter-assay coefficients of variation (CVs) of 2Æ5% and 5%.
F1 + 2 was assessed using a sandwich ELISA (Enzygnost
F1 + 2; Behring Diagnostics GmbH) with intra- and inter-
assay CVs of 5% and 8%.
FVII antigen was measured using a commercial ELISA
(Asserachrom VII:Ag, Diagnostica Stago) according to the
manufacturer’s instructions. The intra- and inter-assay CVs
were 5Æ2% and 6Æ9%.
FXIIa was measured using a sandwich ELISA (Asserachrom
FXIIa, Diagnostica Stago) with intra- and inter-assay CVs of
<7%.
Cleaved high-molecular-weight kininogen (HK) was assessed
by means of sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE) and immunoblotting analysis:
native HK appeared as a band of Mr 130 000, and cleaved HK
as two bands of Mr 107 000 and 98 000.
t-PA antigen was measured using a commercial ELISA
(Imunolyse t-PA; Biopool, Umea, Sweden) according to the
manufacturer’s instructions. The intra- and inter-assay CVs
were 6Æ5% and 8%.
Active PAI-1 was measured using a commercial bioimmu-
noassay (Chromolize PAI-1; Biopool) with intra- and inter-
assay CVs of 2Æ4% and 4Æ5%.
D-dimer was measured using a commercial ELISA (Enzygn-
ost D-dimer; Behring Diagnostics GmbH) according to
manufacturer’s instructions. The intra- and inter-assay CVs
were 10% and 15%.
VWF antigen was measured in citrated plasma by means of a
sandwich ELISA that uses two monoclonal antibodies against
different VWF epitopes (11B6Æ18 and 7G10Æ8) (Mannucci &
Coppola, 1999). The intra- and inter-assay CVs were <8%.
Thrombomodulin was measured in plasma using a commer-
cial sandwich ELISA (Asserachrom Thrombomodulin, Diag-
nostica Stago) with intra- and inter-assay CVs of <10%.
TNF)a was measured in plasma using a direct solid-phase
immunoassay (Enzyme Amplified Sensitivity Immunoassay;
EASIA, Biosource, Flerus, Belgium) with intra- and inter-assay
CVs of 8% and 10%.
sTNFRII was measured using a sandwich ELISA (Quantikine
Human sTNFRII Immunoassay; R&D Systems Inc., Minnea-
polis, MN, USA) with intra- and inter-assay CVs of 2Æ5% and
5Æ1%.
IL-6 was measured in plasma using a sandwich ELISA
(Quantikine Human IL-6 Immunoassay, R & D Systems Inc.)
with intra- and inter-assay CVs of 4Æ2% and 6Æ4%.
sICAM-1 was measured in plasma using a sandwich ELISA
(Parameter Human sICAM-1 Immunoassay; R&D Systems
Inc.) with intra- and inter-assay CVs of 4Æ8% and 10Æ1%.
sVCAM-1 was measured in plasma using a sandwich ELISA
(Parameter Human sVCAM-1 Immunoassay; R&D Systems
Inc.) with intra- and inter-assay CVs of 5Æ9% and 10Æ2%.
sE-selectin was measured in plasma using a sandwich ELISA
(Parameter Human sE-selectin Immunoassay; R&D Systems
Inc.) with intra- and inter-assay CVs of 5Æ0% and 8Æ8%.
Statistical analysis
The descriptive statistics are reported as median values (range)
because of the skewed distribution of the investigated variables.
Inter-group differences were evaluated by means of the
Wilcoxon Mann–Whitney non-parametric test, and correla-
tions by means of Spearman’s test. A P-value of <0Æ05 was
considered significant.
Results
Coagulation and fibrinolysis parameters
The coagulation and fibrinolysis abnormalities of the CHF
patients are shown in Table II. They exhibited significantly
higher plasma levels of fibrinogen (P ¼ 0Æ0001), TAT
(P ¼ 0Æ001), t-PA (P ¼ 0Æ0001) and D-dimer (P ¼ 0Æ0001)
than the controls.
Of the coagulation parameters, prothrombin fragment
F1 + 2 directly correlated with TAT (0Æ644, P ¼ 0Æ001) and
FVII antigen (0Æ607, P ¼ 0Æ001). There was no difference in
any of the coagulation and fibrinolysis parameters between the
patients with ischaemic disease and those with idiopathic
cardiomyopathy.
When the CHF patients were divided on the basis of
anticoagulant treatment, lower levels of TAT (P ¼ 0Æ01),
F1 + 2 (P ¼ 0Æ0001) and FVII (0Æ0001) were observed in the
11 treated patients (Table III), who also had higher levels of
PAI activity (P ¼ 0Æ01).
The nine patients undergoing successful heart transplanta-
tion had significantly reduced plasma fibrinogen (P ¼ 0Æ0001)
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and D-dimer levels (P ¼ 0Æ01), and significantly increased
FVII antigen and FXIIa levels (P ¼ 0Æ0001) (Table II). These
differences were also significant when their pre- and post-
transplant values were compared (the most important differ-
ences are reported in Fig 1). The levels of TAT complexes
remained higher than those of the normal controls (Table II).
In these nine patients before heart transplantation, coagulation
and fibrinolysis parameters were not different from those of
untransplanted patients.
Markers of endothelial dysfunction
The CHF patients had higher plasma VWF (P ¼ 0Æ0001),
thrombomodulin (P ¼ 0Æ01) and t- PA (P ¼ 0Æ0001) levels
than the normal controls, and lower plasma sE-selectin levels
(P ¼ 0Æ001) (Tables II and IV). The markers of endothelial
dysfunction were not significantly different between the
ischaemic and idiopathic cardiomyopathy patients.
Plasma VWF antigen levels tended to correlated directly
with plasma thrombomodulin (r ¼ 0Æ428, P ¼ 0Æ03) and t-PA
antigen levels (r ¼ 0Æ477, P ¼ 0Æ01).
The nine patients studied after heart transplantation
showed a slight reduction in plasma VWF levels
(P ¼ 0Æ01), although these remained higher than in the
controls (P ¼ 0Æ01), and a further increase in thrombomod-
ulin levels (P ¼ 0Æ0001) (Table II). The differences were also
significant when the pre- and post-transplant values were
compared (the most important differences are reported in
Fig 1). Plasma t-PA levels remained high, but those of
sE-selectin normalized (Tables II and IV). In these patients
before heart transplantation, markers of endothelial dysfunc-
tion were not different from those of untransplanted
patients.
Inflammatory cytokines and adhesion molecules
The CHF patients had higher plasma levels of TNF
(P ¼ 0Æ0001), sTNFRII (P ¼ 0Æ0001), IL-6 (P ¼ 0Æ0001),
sICAM (P ¼ 0Æ001) and sVCAM (P ¼ 0Æ0001) than the
normal controls (Table IV). There was no significant differ-
ence in inflammation parameters between the patients with
ischaemic disease and those with idiopathic cardiomyopathy.
The patients receiving anticoagulant treatment had lower
levels of sTNFRII (P ¼ 0Æ01) and sVCAM (P ¼ 0Æ01) than
those who were not (Table III).
The plasma levels of sTNFRII directly correlated with those
of TNF (r ¼ 0Æ422, P ¼ 0Æ03), IL-6 (r ¼ 0Æ481, P ¼ 0Æ01),
sICAM (r ¼ 0Æ473, P ¼ 0Æ02) and sVCAM (r ¼ 0Æ797,
P ¼ 0Æ0001), and there was a correlation between IL-6 and
sICAM levels (r ¼ 0Æ619, P ¼ 0Æ001).
Table II. Plasma coagulation, fibrinolysis and
endothelial parameters in 25 healthy subjects
(controls) and 25 patients with advanced CHF,
including nine patients evaluated after successful
heart transplantation.
Controls
(n ¼ 25)
Total CHF patients
(n ¼ 25)
Transplant patients
(n ¼ 9)
Fibrinogen (g/l) 3Æ0 (1Æ96–3Æ8) 5Æ13*** (2Æ74–7Æ48) 3Æ55* (2Æ35–4Æ87)
TAT (ng/ml) 2Æ4 (1Æ3–4Æ9) 3Æ8** (1Æ6–16Æ8) 4Æ5*** (2Æ9–22Æ2)
F1 + 2 (ng/ml) 1Æ2 (0Æ9–1Æ9) 1Æ0 (0Æ3–3Æ7) 1Æ1 (0Æ3–3Æ1)
FVII (ng/ml) 100 (60–139) 74* (16–138) 145** (80–215)
FXIIa (ng/ml) 2Æ40 (0Æ90–5Æ00) 2Æ50 (1Æ19–4Æ50) 5Æ50*** (2Æ50–8Æ10)
Cleaved HK (% of total HK) 18 (1–32) 18 (8–32) 16 (12–21)
PAI (ng/ml) 14Æ8 (2Æ9–29Æ4) 7Æ6 (0Æ1–80Æ7) 18Æ7 (2Æ6–47Æ3)
t-PA (ng/ml) 6Æ9 (2Æ7–13Æ5) 16Æ0*** (7Æ7–36Æ5) 15Æ1*** (7Æ4–21Æ8)
D-dimer (ng/ml) 15 (7–41) 74*** (12–815) 41*** (32–102)
VWF:Ag (% of normal) 109 (50–204) 264*** (85–720) 175* (109–360)
Thrombomodulin (ng/ml) 17Æ3 (0Æ7–29Æ3) 22Æ7* (13Æ4–55Æ4) 58Æ5*** (23Æ7–83Æ6)
Median values (range in parentheses).
Significance versus controls ***P ¼ 0Æ0001; **P ¼ 0Æ001; *P ¼ 0Æ01.
Significance versus CHF patients P ¼ 0Æ0001; P ¼ 0Æ001; P ¼ 0Æ01.
VWF:Ag, von Willebrand factor antigen; CHF, chronic heart failure; TAT, thrombin–
antithrombin complex; PAI, plasminogen activator inhibitor.
Table III. Plasma levels of the coagulation and inflammation
parameters that were significantly different between the 11 CHF
patients treated with OAT and the 14 CHF patients who were not.
CHF patients not
receiving OAT
(n ¼ 14)
CHF patients
receiving OAT
(n ¼ 11)
TAT (ng/mL) 4Æ9 (2Æ6–16Æ8) 2Æ3* (1Æ6–9Æ2)
F1 + 2 (ng/ml) 1Æ6 (0Æ9–1Æ9) 0Æ6** (0Æ3–3Æ7)
FVII (ng/ml) 101 (21–138) 29** (16–74)
PAI (ng/ml) 5Æ2 (1Æ1–44Æ0) 10Æ5* (0Æ1–80Æ7)
sTNFRII (pg/ml) 5748 (3530–8374) 4374* (2975–7681)
sVCAM (ng/ml) 1360 (613–4608) 882* (401–2042)
Median values (range in parentheses).
Statistical significance **P ¼ 0Æ0001; *P ¼ 0Æ01.
CHF, chronic heart failure; OAT, oral anticoagulant therapy; sVCAM,
soluble vascular cell adhesion molecule; sTNFRII, soluble tumour
necrosis factor II; TAT, thrombin–antithrombin complex; PAI,
plasminogen activator inhibitor.
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In the nine patients studied after heart transplantation, there
was a significant reduction (P ¼ 0Æ01) in the plasma levels of
IL-6 (which, however, remained higher than normal) and
sICAM (which normalized) (Table IV). These differences were
also significant when the pre- and post-transplant values were
compared (the most important differences are reported in
Fig 1). In these patients before heart transplantation, plasma
levels of inflammatory cytokines and adhesion molecules were
not different from those of untransplanted patients.
Correlations between coagulation, fibrinolysis and
endothelial function parameters, inflammatory cytokines
and adhesion molecules
There were statistically significant correlations between the
coagulation and fibrinolysis parameters: fibrinogen directly
correlated with tPA antigen (r ¼ 0Æ512, P ¼ 0Æ009); and PAI
inversely correlated with FVII antigen (r ¼ )0Æ572,
P ¼ 0Æ003).
The coagulation and fibrinolysis parameters correlated with
the endothelial markers: VWF directly correlated with fibrin-
ogen (r ¼ 0Æ511, P ¼ 0Æ009), TAT complexes (r ¼ 0Æ566,
P ¼ 0Æ003) and t-PA antigen (r ¼ 0Æ477, P ¼ 0Æ01), and
sE-selectin directly correlated with cleaved HK (r ¼ 0Æ531,
P ¼ 0Æ006) and D-dimer (r ¼ 0Æ431, P ¼ 0Æ03).
In relation to the coagulation/fibrinolysis and inflammation
parameters, IL-6 levels directly correlated with fibrinogen
(r ¼ 0Æ541, P ¼ 0Æ005) and t-PA antigen (r ¼ 0Æ482,
P ¼ 0Æ01).
There were direct correlations between the markers of
endothelial dysfunction and cytokine and adhesion molecule
levels: VWF correlated with sTNFRII (r ¼ 0Æ486, P ¼ 0Æ01),
IL-6 (r ¼ 0Æ465, P ¼ 0Æ01) and sICAM (r ¼ 0Æ524,
P ¼ 0Æ007), and thrombomodulin with sTNFRII (r ¼ 0Æ456,
P ¼ 0Æ02) and sICAM (r ¼ 0Æ462, P ¼ 0Æ02).
No correlation was found between the patients’ age or
prognosis at 18 months or cardiac graft ischaemic time and the
investigated coagulation, endothelial function and inflamma-
tion parameters.
Discussion
We found that, regardless of its aetiology, advanced CHF was
associated with the activation of coagulation and fibrinolysis,
endothelial dysfunction and increased proinflammatory cyto-
kine and adhesion molecule levels. Most of these abnormalities
paralleled each other, were less in patients treated with OAT
therapy and, although reduced, persisted after successful heart
transplantation even in the absence of any clinical signs of
CHF.
Analysis of the coagulation parameters in our patients
indicated that CHF leads to a hypercoagulable state, with high
levels of thrombin formation markers, such as TAT complexes.
The activation of the coagulation system in CHF has been
Fig 1. Plasma levels of fibrinogen, von Wille-
brand Factor (VWF), D-dimer and interleukin-6
(IL-6) in nine patients with advanced chronic
heart failure before heart transplantation (pre)
and in the same patients after successful heart
transplantation (post). Values are expressed as
median and interquartile range (P-values refer to
the Wilcoxon Mann–Whitney non-parametric
test).
Table IV. Plasma levels of inflammatory
cytokines and adhesion molecules in 25 healthy
subjects (controls) and 25 patients with
advanced CHF, including nine patients after
successful heart transplantation.
Controls
(n ¼ 25)
Total CHF patients
(n ¼ 25)
Transplant patients
(n ¼ 9)
TNF (pg/ml) 17Æ8 (12Æ7–25Æ7) 31Æ1*** (19Æ6–93Æ1) 22Æ5* (15Æ9–41Æ3)
sTNFRII (pg/ml) 2555 (1762–3557) 5257*** (2975–8374) 6238*** (3478–12062)
IL-6 (pg/ml) 0Æ12 (0Æ00–4Æ60) 7Æ24*** (0Æ76–232Æ16) 3Æ16*** (1Æ35–6Æ79)
sICAM (ng/ml) 348 (210–605) 486** (167–2432) 305 (285–480)
sVCAM (ng/ml) 551 (226–898) 1027*** (401–4608) 849*** (660–1198)
sE-selectin (ng/ml) 45Æ0 (4Æ0–150Æ0) 26Æ0** (16Æ0–81Æ0) 45Æ6 (19Æ2–70Æ8)
Median values (range in parentheses).
Significance versus controls ***P ¼ 0Æ0001; **P ¼ 0Æ001; *P ¼ 0Æ01.
Significance versus CHF patients P ¼ 0Æ01.
CHF, chronic heart failure; TNF, tumour necrosis factor; IL-6, interleukin 6; sVCAM, soluble
vascular cell adhesion molecule; sICAM, soluble intercellular adhesion molecule; sTNFRII,
soluble tumour necrosis factor II; E-selectin, endothelial-selectin.
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previously reported (Yamamoto et al, 1995; Davis et al, 2000),
and suggested to be important in disease progression and
thromboembolic complications (Davis et al, 2000). On the
basis of the results of recently published clinical trials,
the expected incidence of thromboembolic events is approxi-
mately 2% a year (Isnard & Komajda, 2001), but it is higher in
patients with severe CHF, who have an annual stroke risk of
4% (Brown & Cleland, 1998). Our patients had high levels
of fibrinogen, which has been identified as a major
independent risk factor for cardiovascular disease (Juhan-
Vague, 1996); they also had high levels of D-dimer, a marker
of fibrinolysis (probably secondary to coagulation activation)
that has been found to be associated with the risk of
myocardial infarction (Cushman et al, 1999).
There is still no consensus concerning the usefulness of
antithrombotic therapy in CHF (except in the presence of
atrial fibrillation) because of the relatively high (2Æ3–6Æ8%) risk
of major haemorrhages during anticoagulant treatment
(Koniaris & Goldhaber, 1998; Isnard & Komajda, 2001).
However, there is a need to extend the indications for
treatment in CHF patients (Sirajuddin et al, 2002). Eleven of
our patients received OATs, and had lower levels of coagula-
tion activation markers than those who did not (Table III).
The very low F1 + 2 levels in the patients taking anticoagulant
treatment explain why they were not increased in the CHF
patients as a whole (Table II). The association between OAT
treatment and lower levels of the markers of thrombin
generation has been previously described (Bruhn et al, 1992),
and may be related to a favourable effect induced by the
reduction in hypercoagulability, although no clear correlation
between plasma F1 + 2 levels and the degree of anticoagula-
tion has yet been demonstrated. FVII levels were also very low
in our patients receiving anticoagulant treatment, and this may
be protective as high levels have been associated with increased
cardiovascular mortality (Juhan-Vague, 1996). We found that
the changes in coagulation after heart transplantation
remained (although to a lesser degree), and these have been
correlated with accelerated coronary sclerosis and cardiac
transplant rejection (Hunt et al, 1993; Segal et al, 2001).
The plasma levels of inflammatory cytokines, adhesion
molecules and markers of endothelial dysfunction in our CHF
patients were higher than in the normal controls, and
remained high after heart transplantation, albeit to a lesser
extent. High plasma levels of VWF, which have been associated
with a hypercoagulable state in CHF patients (Gibbs et al,
2001), were observed also in our transplanted patients in
agreement with a previous study (Hunt et al, 1993); these
patients had normal levels of sE-selectin as previously reported
(Andreassen et al, 1998). High serum levels of proinflamma-
tory cytokines have been related to the pathogenesis of
allograft rejection, although a systematic relationship between
cytokine levels and histological rejection has been excluded
(Grant et al, 1996). Persistent intracardiac TNF expression
may contribute to the development of cardiac allograft
hypertrophy (Stetson et al, 2001). However, given the potential
immune stimulation caused by a transplanted heart and the
immune suppression caused by therapy, the differences in the
pre- and post-transplantation levels of inflammation markers
in our patients should be interpreted cautiously.
The activation of the immune system in patients with CHF
is well known, but its origin remains elusive. Two hypotheses
have been proposed on the basis of experimental and clinical
data: one hypothesized that bowel wall oedema leads to
bacterial translocation, with subsequent endotoxin release and
immune activation (Anker et al, 1997), and the second
hypothesized that the heart is the main source of cytokines,
as shown by the fact that TNF a is produced by a failing, but
not a normal, myocardium (Habib et al, 1996; Torre-Amione
et al, 1996). However, a single source of cytokine production
(gut or heart) does not seem to be sufficient to explain the
multiple organ involvement and systemic inflammation of
CHF, which have also been related to systemic hypoxia
(Hasper et al, 1998). Whatever the cause of the immune
system stimulation, an intermediate mechanism may be the
activation of the coagulation system: our patients treated with
OATs, which efficiently reduced the markers of hypercoagu-
lability, showed reduced levels of sensitive inflammation
markers, such as sTNFRII and sVCAM (Table III). A link
between the activation of the coagulation and immune systems
in CHF was also supported by our observation of direct
correlations between the markers of both systems. It has been
demonstrated that thrombin can activate macrophage adhe-
sion and induce the production of IL-6 and monocyte
chemoattractant protein-1 in an in vivo animal model (Szaba
& Smiley, 2002), and it is known that immune system
activation may promote coagulation as there is evidence that
IL-6 induces the increased expression of tissue factor,
fibrinogen, FVIII and VWF, and activates endothelial cells
(Kerr et al, 2001).
In conclusion, the novel findings of this study are that: (i)
a thrombophilic state is closely associated with markers of
endothelial dysfunction and systemic inflammation in
advanced CHF; (ii) after a successful heart transplantation,
these abnormalities still persist (although to a lesser extent)
even in the absence of clinical signs of CHF; and (iii) OAT
treatment tends to normalize not only the alterations in
coagulation, but also the parameters of inflammation. Our
findings suggest that OAT treatment may be beneficial in
patients with advanced CHF, although a larger and random-
ized study is necessary to verify whether or not the benefits of
prolonged OAT treatment outweigh its side effects.
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